Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Accounts Payables history
Currency unavailable · from the cash flow
No Accounts Payables data reported for this period type.
Accounts Payables vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.66M USD | +88.8% | +10.3% | 5.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $5.43M USD | — | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4.34M USD | +345.5% | — | 21.7% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4M USD | +845.6% | — | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $2.21M USD | -172.7% | +55.8% | — |
| LTM Mar 2026 | $190K USD | +249.6% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +249.6% | +33.0% | 13.5% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.